We are live on
!
Find out more
TAM
TFG Asset Management Portfolio holdings
AUM
$635M
Turnover
36.96%
1-Year Est. Return
28.07%
This Fund
S&P 500
This Quarter
Est. Return
+13.2%
1 Year Est. Return
+28.07%
3 Year Est. Return
+72.07%
5 Year Est. Return
+87.41%
10 Year Est. Return
+132.97%
AUM
$635M
AUM Growth
+$120M
(+23%)
Cap. Flow
+$71.2M
Cap. Flow
% of AUM
11.21%
Top 10 Holdings %
Top 10 Hldgs %
74.01%
Holding
46
New
10
Increased
16
Reduced
5
Closed
7
Avg Time Held Equity + Options
1.1
years
Top 10 Avg Time Held Equity + Options
1.2
years
Top 20 Avg Time Held Equity + Options
1.2
years
Avg Time Held Equity only
1.4
years
Top 10 Avg Time Held Equity only
1.5
years
Top 20 Avg Time Held Equity only
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UiPath
PATH
|
+$61.3M |
| 2 |
Alkami Technology
ALKT
|
+$9.91M |
| 3 |
Celcuity
CELC
|
+$7.4M |
| 4 |
Relay Therapeutics
RLAY
|
+$5.64M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$4.17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Warner Bros
WBD
|
+$18.2M |
| 2 |
Praxis Precision Medicines
PRAX
|
+$5.14M |
| 3 |
Axsome Therapeutics
AXSM
|
+$4.35M |
| 4 |
Soleno Therapeutics
SLNO
|
+$3.42M |
| 5 |
MapLight Therapeutics
MPLT
|
+$2.28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 61.09% |
| 2 | Healthcare | 29.27% |
| 3 | Energy | 5.33% |
| 4 | Miscellaneous | 3.27% |
| 5 | Communication Services | 1.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
UiPath
PATH
$6.81B
| $336M | 52.98% |
30,950,000
+5,742,372
| +23% | +$61.3M |
2022 Q1
17 quarters
|
|
2
Kolibri Global Energy
KGEI
$230M
| $33.8M | 5.33% |
6,834,504
| – | – |
2023 Q4
10 quarters
|
|
3
Autolus Therapeutics
AUTL
$450M
| $15.2M | 2.39% |
9,500,000
| – | – |
2018 Q2
32 quarters
|
|
4
Lyft
LYFT
$6.24B
| $14.6M | 2.3% |
1,000,000
| – | – |
2021 Q4
18 quarters
|
|
5
Definium Therapeutics
DFTX
$4.6B
| $13.5M | 2.13% |
286,990
+86,996
| +43% | +$2.15M |
2026 Q1
1 quarter
|
|
6
Workiva
WK
$3.95B
| $12.1M | 1.91% |
250,000
| – | – |
2025 Q2
4 quarters
|
|
7
Sprinklr
CXM
$1.31B
| $11.4M | 1.79% |
2,200,000
| – | – |
2022 Q1
17 quarters
|
|
8
MBX Biosciences
MBX
$2.35B
| $11.2M | 1.77% |
203,543
+58,063
| +40% | +$2.03M |
2025 Q3
3 quarters
|
|
|
9
Alkami Technology
ALKT
$1.48B
| $10.9M | 1.71% |
+600,284
| New | +$9.91M |
2026 Q2
0 quarters
|
|
10
Celldex Therapeutics
CLDX
$2.19B
| $10.8M | 1.7% |
290,441
-21,875
| -7% | -$707K |
2024 Q4
6 quarters
|
|
|
11
Relay Therapeutics
RLAY
$3.74B
| $10.7M | 1.68% |
570,311
+388,768
| +214% | +$5.64M |
2026 Q1
1 quarter
|
|
12
Arrowhead Research
ARWR
$8.25B
| $10.6M | 1.67% |
130,484
+3,286
| +3% | +$243K |
2025 Q3
3 quarters
|
|
13
Pharvaris
PHVS
$2.11B
| $10.2M | 1.61% |
295,627
+74,016
| +33% | +$2.24M |
2025 Q1
5 quarters
|
|
14
Alkermes
ALKS
$6.56B
| $9.95M | 1.57% |
189,979
+30,188
| +19% | +$1.18M |
2025 Q2
4 quarters
|
|
15
Immunovant
IMVT
$5.76B
| $9.86M | 1.55% |
255,934
+37,427
| +17% | +$1.14M |
2025 Q1
5 quarters
|
|
|
16
CALL
Axsome Therapeutics
AXSM
$8.5B
| $8.57M | 1.35% |
35,000
| – | – |
2026 Q1
1 quarter
|
|
17
Silence Therapeutics
SLN
$558M
| $8.39M | 1.32% |
764,256
+134,095
| +21% | +$943K |
2025 Q4
2 quarters
|
|
18
Dyne Therapeutics
DYN
$2.81B
| $7.92M | 1.25% |
356,657
+98,525
| +38% | +$1.83M |
2025 Q2
4 quarters
|
|
|
19
Ionis Pharmaceuticals
IONS
$7.1B
| $7.7M | 1.21% |
97,173
+55,409
| +133% | +$4.17M |
2026 Q1
1 quarter
|
|
20
Agios Pharmaceuticals
AGIO
$1.85B
| $7.63M | 1.2% |
205,579
+40,740
| +25% | +$1.24M |
2025 Q4
2 quarters
|
|
21
Harmony Biosciences
HRMY
$2.18B
| $7.32M | 1.15% |
201,036
+81,696
| +68% | +$2.58M |
2025 Q4
2 quarters
|
|
22
Krystal Biotech
KRYS
$9.79B
| $7.31M | 1.15% |
19,668
| – | – |
2025 Q3
3 quarters
|
|
23
Annexon
ANNX
$696M
| $7.09M | 1.12% |
1,242,455
-50,000
| -4% | -$276K |
2024 Q2
8 quarters
|
|
|
24
Celcuity
CELC
$2.93B
| $6.71M | 1.06% |
+64,110
| New | +$7.4M |
2026 Q2
0 quarters
|
|
|
25
DELISTED
Warner Bros
WBD
| $6.67M | 1.05% |
250,000
-673,725
| -73% | -$18.2M |
2026 Q1
1 quarter
|
|
Similar funds
GRR
GAM
MPIA
AFG
MCM
MAM
BAM
LRIA
TFG Asset Management's Q2 2026 Portfolio in Review
As of Q2 2026, TFG Asset Management held 46 positions worth $635M, up 23% from $515M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
TFG Asset Management deployed $71.2M of net new capital in Q2 2026, opening 10 new positions and adding to 16 existing holdings. Its largest new stake was Alkami Technology: 600,284 shares worth $10.9M.
By sector, the portfolio is most concentrated in Technology at 61% of assets, down from 63% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Warner Bros, an estimated $18.2M trimmed.
- TFG Asset Management's largest Q2 2026 buy was Alkami Technology: 600,284 shares worth $10.9M.
- TFG Asset Management added most to UiPath in Q2 2026, an estimated $61.3M increase.
- TFG Asset Management's biggest Q2 2026 reduction was Warner Bros, cutting an estimated $18.2M.
- TFG Asset Management fully exited Praxis Precision Medicines in Q2 2026, selling an estimated $5.14M.
- TFG Asset Management's ten largest holdings make up 74% of its $635M portfolio in Q2 2026.
- TFG Asset Management opened 10 new positions and closed 7 in Q2 2026.
- TFG Asset Management's portfolio value rose 23% quarter-over-quarter to $635M.
Based on TFG Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.